Nykob (Olanzapine)

Olanzapine is an atypical antipsychotic used in the management of several psychiatric disorders.

• Schizophrenia: reduces psychotic symptoms such as delusions and hallucinations.
• Bipolar I disorder (manic phase): controls acute manic episodes and helps maintain mood stability.
• Schizoaffective disorder: alleviates both psychotic and mood components of the condition.
• Maintenance therapy: helps prevent relapse of psychotic symptoms after stabilization.

• Olanzapine acts as a high‑affinity antagonist at dopamine D2 and serotonin 5‑HT2A receptors, with additional activity at histamine H1, muscarinic, and adrenergic receptors. By blocking dopamine and serotonin signaling in key brain pathways, it modulates neurotransmission that underlies psychotic and mood symptoms, leading to clinical improvement.

Olanzapine may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

• Weight gain: increased appetite and caloric intake.
• Sedation: drowsiness or feeling of being unusually tired.
• Dry mouth: reduced salivation.
• Constipation: slowed gastrointestinal motility.
• Elevated triglycerides: rise in blood lipid levels.
• Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: rare but potentially life‑threatening reaction.
• Hyperglycaemia and new‑onset diabetes mellitus.
• Tardive dyskinesia: persistent involuntary movements.
• Seizures: increased risk in susceptible individuals.
• Severe neutropenia: marked reduction in white‑blood cell count.
• Hepatotoxicity: liver enzyme elevations or injury.

When prescribing olanzapine, clinicians should consider several safety aspects.

• Metabolic monitoring: regularly assess weight, glucose, and lipid profiles.
• Cardiovascular assessment: monitor blood pressure and heart rate, especially during initiation.
• CNS effects: advise patients about sedation and avoid operating heavy machinery.
• Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed.
• Elderly with dementia: increased risk of mortality; avoid unless essential.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olanzapine interacts with several drug classes that can alter its effectiveness or safety profile.

Major Interactions (Avoid)

• CYP1A2 inhibitors (e.g., fluvoxamine): may increase olanzapine plasma levels.
• CNS depressants (e.g., benzodiazepines, alcohol): additive sedation.

Moderate Interactions (Monitor Closely)

• CYP2D6 substrates (e.g., metoprolol): olanzapine may affect their metabolism.
• Anticholinergic agents: may exacerbate dry mouth and constipation.
• Smoking: induces CYP1A2, potentially lowering olanzine ? 
• Antihistamines: may increase sedation.
• Lithium: combined use may heighten neuro‑excitatory ?